Developing effective inhibitors that simultaneously target HIF and IGF1R, along with implementing combination therapies, may significantly improve the prognosis of patients with this aggressive cancer, providing new strategies and targets for comprehensive GBM treatment. The gene discussed is IGF1R; the disease is glioblastoma.